AC Immune SA.
ACIU.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
AC Immune SA is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics and diagnostics for neurodegenerative diseases. The company focuses on protein misfolding diseases, including Alzheimer's disease, Parkinson's disease, and other related disorder...Show More
Better Health for All
10
AC Immune SA's core business is entirely dedicated to developing therapeutics and diagnostics for neurodegenerative diseases like Alzheimer's and Parkinson's, with 100% of its pipeline focused on these areas, indicating a revolutionary health impact.
1
The company has no products with significant negative health impacts. It has a broad pipeline with one Phase 3 program and five in Phase 2,
2
and consistently invests in R&D, including pioneering precision therapeutics and novel approaches, securing over $4.5 billion in potential milestone payments from partnerships.
3
The company is developing therapies for Down syndrome-related Alzheimer's disease,
4
evaluating ACI-24.060 in individuals with Down syndrome and early Alzheimer's disease,
5
and Morphomer® Tau small molecule aggregation inhibitors for NeuroOrphan indications.
6
Clinical trials are double-blind, placebo-controlled,
7
and approved by Ethics Committees,
8
with participants providing informed consent.
9
The Phase 2b Reτain trial aims to arrest Tau pathology propagation, contributing to delaying cognitive decline.
10
However, a Phase 1b/2a study reported frequent adverse events like injection site reactions (16.7%–100%) and headaches (16.7%–50%),
11
nine serious adverse events in six participants,
12
and asymptomatic microhaemorrhages (ARIA-H) in some participants,
13
though no adverse events led to study discontinuation.
14
The company's risk transparency is good, with comprehensive reporting of adverse events and dose escalation reviewed by an independent Data Safety Monitoring Board.
15
Mental health initiatives are limited to performing Columbia-Suicide Severity Rating Scale (C-SSRS) and Neuropsychiatric Inventory (NPI) in trials.
16
For healthcare data responsibility, AC Immune SA and Johnson & Johnson Innovative Medicine grant access to group-level data (analysis datasets) only in early phase clinical trials.
17
Fair Money & Economic Opportunity
0
AC Immune SA is a clinical-stage biopharmaceutical company focused on developing therapeutics and diagnostics for neurodegenerative diseases.
1
The company's core business involves clinical trials and drug development, not financial services, lending, or deposit services to consumers.
2
Therefore, all Key Performance Indicators related to 'Fair Money & Economic Opportunity' are not applicable to the company's operations, as it does not offer financial products or services.
3
Fair Pay & Worker Respect
0
The provided articles do not contain specific, quantifiable data points for any of the KPIs under the 'Fair Pay & Worker Respect' value. While some articles mention policies or commitments related to fair treatment, equal opportunity, and a safe work environment, these are not concrete metrics such as living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rates, pay equity ratios, worker engagement scores, voluntary turnover rates, labor violation incidents, insecure contract share, or health insurance coverage. The mention of 'No regulatory actions, violations, fines, or compliance issues are mentioned' in one article is an absence of reporting, not a concrete data point of zero incidents, and thus does not constitute scorable evidence.
1
Therefore, no KPIs can be scored based on the evidence provided.
Fair Trade & Ethical Sourcing
0
The provided articles do not contain specific, quantifiable information regarding fair trade certifications, supplier audit frequency, substantiated forced or child labor incidents, supply chain traceability coverage, remediation speed for violations, the percentage of supplier contracts with enforceable ethical sourcing clauses, the share of spend on high-risk materials, or supplier diversity spend.
1
General statements about ethics or a Code of Business Conduct are not sufficient to score these specific, quantitative KPIs.
Honest & Fair Business
-10
AC Immune SA has a comprehensive whistleblower policy, effective October 1, 2025, which includes an anonymous external hotline (online and phone) and a secure web form for reporting concerns.
1
The company explicitly states it does not tolerate retaliation against anyone who raises a compliance concern in good faith.
2
The SEC requires the company to provide a facility for handling complaints related to accounting, internal controls, or auditing matters.
3
The company also maintains an anti-corruption policy, effective October 1, 2025, which prohibits bribes, inducements, and gifts over CHF 100 without written approval from an executive manager, and forbids gifts to government officials or cash equivalents.
4
Training on anti-bribery and corruption is provided, and the policy covers compliance with laws regarding business relations with healthcare professionals.
5
The company's Code of Business Conduct and Ethics states it strives to promote the application of its standards by those with whom it does business and prohibits engaging third parties to perform prohibited acts, but does not specify the extent of independent verification of these ethical claims.
6
Kind to Animals
-50
AC Immune SA uses animals for drug testing and development, including non-human primates and mice.
1
Animal experiments are carried out in accordance with German animal welfare law and have received approval from the government of Upper Bavaria.
2
One study involved 31 mice (APPPS1 and ApoE knock-out mice) for evaluating a vaccine.
3
An SEC filing from September 2016 confirms the company's use of animal testing as part of its drug development.
4
No War, No Weapons
0
No evidence available to assess AC Immune SA on No War, No Weapons.
Planet-Friendly Business
0
No evidence was found in the provided articles regarding AC Immune SA's (ACIU.US) planet-friendly business practices or environmental performance. The articles primarily discuss the company's focus on developing treatments for neurodegenerative diseases, clinical trials, partnerships, and financial results.
1
One article, while including 'Summary for ACIU.US' in its title, detailed sustainability initiatives specifically for AstraZeneca, which is a different entity and therefore not applicable to this assessment.
2
Respect for Cultures & Communities
0
No specific, concrete evidence was found in the provided articles regarding AC Immune SA's performance on any of the KPIs related to Respect for Cultures & Communities.
1
The articles discuss general supplier information and career opportunities but do not contain data on community partnerships, cultural impact assessments, local investment, cultural appropriation incidents, or other relevant metrics.
2
Safe & Smart Tech
10
AC Immune SA demonstrates good practices in user data control, data minimization, and regulatory compliance. The company's privacy policy, updated in May 2025, explicitly states compliance with the European General Data Protection Regulation (GDPR) and the Swiss Federal Data Protection Act (FDPA).
1
Users are granted rights to information, access, correction, deletion, limitation of data processing, objection, and withdrawal of consent.
2
For data minimization, the company states that data is stored only as long as necessary for its purpose or as required by law, and specifically limits the use of personal data for shareholder votes to counting and eligibility confirmation.
3
No specific data was provided for other KPIs, leading to their omission.
Zero Waste & Sustainable Products
0
No evidence available to assess AC Immune SA on Zero Waste & Sustainable Products.